News

Shengshi Tyco was rated as the most growing innovative pharmaceutical enterprise

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-08-09
  • Views:0

(Summary description)Today, there is good news from the 6th China Biomedical Innovation Cooperation Conference and the 2022 China biomedical industry value list award ceremony: Shengshi Tyco was selected into the list of "top 10 small molecule innovative drug enterprises with the most growth". In the past month, Shengshi Tyco has successively approved two new drug products under development by both China and the United States, opening a new journey for innovative drugs to go to sea.

Shengshi Tyco was rated as the most growing innovative pharmaceutical enterprise

(Summary description)Today, there is good news from the 6th China Biomedical Innovation Cooperation Conference and the 2022 China biomedical industry value list award ceremony: Shengshi Tyco was selected into the list of "top 10 small molecule innovative drug enterprises with the most growth". In the past month, Shengshi Tyco has successively approved two new drug products under development by both China and the United States, opening a new journey for innovative drugs to go to sea.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-08-09
  • Views:0

Shengshi Tyco was rated as the most growing innovative pharmaceutical enterpriseToday, there is good news from the 6th China Biomedical Innovation Cooperation Conference and the 2022 China biomedical industry value list award ceremony: Shengshi Tyco was selected into the list of "top 10 small molecule innovative drug enterprises with the most growth". In the past month, Shengshi Tyco has successively approved two new drug products under development by both China and the United States, opening a new journey for innovative drugs to go to sea.


The current China Biomedical Innovation Cooperation Conference focuses on cutting-edge technology information, interprets the latest industrial policies, and links industry, University, research, and funding. Among them, Wanyi medicine and China Medical Research Institute made comprehensive judgments from multiple dimensions, such as strategic elements, product elements, competitive elements, team elements, commercialization elements and value elements, and conducted in-depth evaluation on industries, industries and enterprises. After collection, data return visit, systematic research and other evaluation processes, the "2022 China biomedical industry value list" was formed. The list was officially released at the plenary meeting.


Shengshi Tyco was founded in Suzhou Industrial Park in 2010. The core team has decades of experience in the whole life cycle of international drugs, and is committed to the R & D and industrialization of small molecule innovative drugs for breakthrough therapies. Relying on the integrated drug R & D technology platform and diversified business vision, the company has built a rich pipeline of innovative drugs, covering many disease fields such as glucose lowering, anticancer and rare diseases.

Recently, these three layout areas have achieved continuous success. In the field of glucose lowering, shenggliptin phosphate, an original new drug DPP-4 inhibitor, has entered the final stage of phase III clinical treatment, and is expected to fill the gap of domestic original oral glucose lowering drugs; Three of the anticancer drugs under research have entered the clinic. The FGFR / VEGFR dual target inhibitor cgt-6321 has been carried out in phase I clinical trials in advanced solid tumors, and this drug is expected to become a potential first in class drug; CXCR4 antagonist cgt-1881 is used for hematopoietic stem cell mobilization, and oral administration is more convenient; Cgt-9475, a new generation ALK / ret inhibitor, is expected to solve several major clinical pain points such as drug resistance and brain metastasis in the treatment of lung cancer. The first two projects have obtained the clinical license of the US FDA, which is a solid step for the company's innovative drugs to go to sea. In addition, the first domestic copy of the treatment of rare disease multiple sclerosis will be officially launched in the near future, which will benefit domestic patients with high quality and more affordable prices.

The

The listing application of Shengshi Tyco's new hypoglycemic drug Shenggliptin was accepted

Today, Shengshi Tyco has accepted the marketing application (NDA) of Shenggliptin, a DPP-4 inhibitor, submitted to the National Drug Administration (NMPA) for the treatment of type 2 diabetes.
2023-02-02
Quantity

"Quantity" Half Achieves Double Prosperity: Tyco's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.
2022-10-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO